A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Inclusion criteria

• Adults > 18 years of age
• Undergone allogeneic HSCT
• Written informed consent
• Patients with treatment refractory infections with adenovirus, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) will be included in case of fulfilling following criteria:

Patient with Adenovirus Infection:

• Antiviral treatment with cidofovir for at least 7 days

• no virus load decrease ( ≤ 1 log) or virus load increase on treatment for at least 7 days or
• cluster of differentiation 3 (CD3) + cells < 300/µL on treatment for at least 7 days
• Or if antiviral treatment is contraindicated

Patient with EBV:

• After receipt of at least one anti-cluster of differentiation 20 antigen (CD20)-antibody treat-ment (375 mg/m2)

• No Virus load decrease (≤ 1 log) or virus load increase 7 days after receipt of treatment or
• CD3+ cells < 300/µL 7 days after receipt of treatment or
• Clinical progression

Patient with CMV:

• Antiviral treatment with ganciclovir or foscavir for 14 days

• No Virus load decrease (≤ 1 log) or virus load increase on day 14
• Or if > 2 recurrences despite antiviral treatment with ganciclovir or foscavir for 14 days and CD3+ cells < 300/µL
• Or if antiviral treatment is contraindicated -

Patient Exclusion Criteria:

• graft-versus-host disease (GVHD) > grade 2 at the time point of planned infusion
• Known allergy to iron-dextran or murine antibodies